Divis Laboratories has target of Rs 587, says Technical Analyst, Ashwani Gujral.
Gujral told CNBC-TV18, "Divis Laboratories hasn’t moved but we would see alternative pharma stocks like Ranbaxy, Orchid have moved. So it’s a good idea to get into this at about Rs 515, targets could be closer to Rs 587.”
Source: Moneycontrol
DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.
No comments:
Post a Comment